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CytokinesDendritic cells (DC) are professional antigen-presenting cells that have the ability to detect infectious
materials; antigens to T lymphocytes, and serve as a bridge between innate and adaptive immunities. DC
express the ATP-binding cassette transporters P-glycoprotein (P-gp). P-gp is a 170-kDa transmembrane
protein encoded by the mdr-1 gene, a member of highly conserved superfamily of ATP-binding cassette
transport proteins. Functionally, P-gp transporters have been described to be required for efﬁcient DC and T
cell migration. We report for the ﬁrst time, at the best of our knowledge, P-gp is also required for DC
development and differentiation in mouse bone marrow-derived DC. In this study, we found that an mdr-1
gene and P-gp protein level was increased during DC development and LPS-induced maturation. Moreover,
the activity of P-gp was increased LPS-induced DC maturation. Next, we have attempted to determine
whether the modulation of P-gp regulates surface molecules expression and cytokine production in DC.
Speciﬁcally, down-regulation of P-gp by Venlafaxine (VLX) inhibits the differentiation of DC and cytokine
production, such as IL-1, IL-10, and IL-12 during DCmaturation. Moreover, the P-gp-decreased DC by VLX was
displayed impaired induction of T cell polarizations, proliferation, and cytokine production, including IFN-γ,
IL-4, and IL-2. Taken together, these ﬁndings also broaden current perspective concerning our understanding
of the immunopharmacological functions of VLX and the development of therapeutic adjuvants for the
treatment of DC-related acute and chronic diseases.+82 55 382 8090.
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Dendritic cells (DC) are professional antigen-presenting cells (APC)
that represent a bridge between innate and adaptive immunity [1, 2]. DC
have the ability to detect tumor cells, and sample and present antigens to
T lymphocytes, while at the same time preventing immune responses
against self-tissues [3, 4]. DC are derived from host bone marrow,
developing ﬁrst into immature DC and upon activation, progress to
matureDC.MatureDCpresent antigen inconjunctionwithco-stimulatory
molecules such as B7-families and major histocompatibility complex
(MHC) class molecules, and produce a range of cytokines, leading to the
initiation of a speciﬁc immune response [5]. A critical property of DC is
their ability to respond to environmental stimuli, which determine their
ﬁnalmaturationordifferentiation status [3, 6]. For example, responding totumor antigens, pathogens binding to Toll-like receptors [7], heat shock
proteins, innate cytokines [8], and inﬂammation cytokines, can lead to DC
maturation and subsequent T cell immune responses [9]. Moreover, DC
have been recognized as powerful APC, playing a key role in antitumor
host responses [10, 11], and inducing primary T-cell responses in vitro and
in vivo, which has generated widespread interest in DC-based immuno-
therapy against several types of cancer [12, 13].
P-glycoprotein (P-gp) is a170-kDa trans-membraneproteinmember
of a highly conserved superfamily of ATP-binding cassette transport
proteins, and is encoded by themdr-1 gene [14]. In addition to its ability
to efﬂux toxins, P-gp also plays a role in the resistance to pathogens as it
is expressed on various tissues, including peripheral blood lymphocytes
and DC [15, 16]. Further, because of its ability to efﬂux toxins [17],
overexpression of P-gp contributes to chemotherapeutic drug resistance
[18], and thus remains a critical barrier to successful chemotherapy in
cancerpatients treatedwithdrugs suchas verapamil (VRP), cyclosporine
A (CsA) [19], and venlafaxine (VLX) [20]. VRP andCsA, a typical inhibitor
of P-gp activity, particularly are used in numerous studies for P-gp
function [21, 22]. Recently, P-gp has been reported to be expressed incense.
Table 1
siRNA of P-gp inhibits the expression of costimulatory molecules (CD80, CD86 and CD40), MHC class I, and II on LPS-stimulated CD11c+ DC.
% of positive cella (MFI)b
Surface Ag Medium siRNA LPS siRNA+LPS
CD80 74±2 (256±21) 71±1 (241±15)* 86±3 (950 ±36) ## 74±2 (70±28)**
CD86 75 ±14 (435±22) 78±2 (421±47) 80±1 (1205±47) ## 76±3 (7232±86)**
MHC I 74±2 (87±5) 73±1 (86±1) 81±3 (254±23) ## 75±1 (196±23)**
MHC II 80±1 (230±12) 79±3 (211±23)* 87±2 (470±12) ## 85±1 (341±21) **
*, ** The statistical signiﬁcance between samples with and without siRNA of P-gp is indicated (##Pb0.01 vs unstimulated DC (medium); **Pb0.01 vs LPS-stimulated DC).
a BM-derived DC were cultured in the absence or presence of siRNA of P-gp following the LPS (200 ng/ml) stimulation for 24 h. The expression of surface molecules was analyzed
by FACSCalibur. Two-color ﬂow cytometry was used to determine the level of Ag expression on CD11c+ DC.
b MFI, Mean ﬂuorescence intensity. The results are from one of the three experiments performed.
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nodes via afferent lymphatic vessels. In the human skin explants system,
it was described that antibodies or drugs that antagonize P-pg, such as
VRP, block this migration [16].
Little is known about the role of P-gp in DC maturation,
differentiation, and during T cell interaction and the subsequent
immune response. The functions of P-gp in immune responses are still
unclear. Therefore, in this study, we sought to examine the effects of
P-gp down-regulation on the development, maturation, and differ-
entiation of DC and how this affects T cell proliferation and
polarization. Taken together, these data identify a novel physiological
function for P-gp in DC.
2. Materials and methods
2.1. Animals
Male 8–12-week-old C57BL/6 (H-2Kb and I-Ab) and BALB/c (H-2Kd
and I-Ad)micewere purchased from the Korean Institute of Chemistry
Technology (Daejeon, Korea). They were housed in a speciﬁc
pathogen-free environment within our animal facility for at least
1 week before use. All mouse work was approved by the IACUC and
was performed in our IACUC approved facility.
2.2. Reagents and Abs
Recombinant mouse (rm)GM-CSF and rmIL-4 were purchased
from R&D Systems (Minneapolis, MN USA). Dextran-FITC (molecular
mass, 40,000), and LPS (from Escherichia coli 055:B5) were obtained
from Sigma-Aldrich. An endotoxin ﬁlter (END-X) and an endotoxin
removal resin (END-X B15) were acquired from Associates of Cape
Cod. Cytokine ELISA kits for murine IL-12 p70, IL-4, IL-6, IL-1α, and
IFN-γ were purchased from BD Pharmingen (Rockville, MD, USA).
FITC- or PE-conjugated mAbs used to detect the expression of CD11c
(HL3), CD80 (16-10A1), CD86 (GL1), IAb β-chain (AF-120.1), H2Kb
(AF6-88.5), and CD4 (L3T4), or the intracellular expression of IL-12
p40/p70 (C15.6), and IL-10 (JESS-16E3) by ﬂow cytometry, as well as
isotype-matched control mAbs, biotinylated anti-CD11c (N418) mAb,
were purchased from BD Pharmingen.Table 2
siRNA of P-gp inhibits the production of cytokines (IL-1α and IL-12) on LPS-stimulated CD
pg/ml/106 cellsa
Medium siRNA
IL-1α 21±2 23±1
IL-12 12±0.5 15±2
*, ** The statistical signiﬁcance between samples with and without siRNA of P-gp is indicat
a BM-derived DC were cultured in the absence or presence of siRNA of P-gp following th
measured by ELISA with magnetic bead-puriﬁed DC (1×106 cells) 24 h after LPS stimulatio2.3. Generation and culture of DC
DC were generated from murine bone marrow (BM) cells. Brieﬂy,
BMwas ﬂushed from the tibiae and femurs of C57BL/6 and depleted of
red cells with ammonium chloride. The cells were plated in six-well
culture plates (106 cells/ml; 3 ml/well) in OptiMEM (Invitrogen Life
Technologies, Carlsbad, CA, USA) supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin, 5×10−5 M 2-ME, 10 mM HEPES (pH 7.4), 20 ng/ml
rmGM-CSF and rmIL-4 at 37 °C, 5% CO2. On day 3 of the culture,
ﬂoating cells were gently removed, and fresh medium was added. On
day 6 of the culture, nonadherent cells and loosely adherent
proliferating DC aggregates were harvested for analysis or stimula-
tion, or, in some experiments, replated in 60-mmdishes (106 cells/ml;
5 ml/dish). On day 6, 80% or more of the nonadherent cells expressed
CD11c. In certain experiments, to obtain highly puriﬁed populations
for subsequent analyses, the DC were labeled with bead-conjugated
anti-CD11c mAb (Miltenyi Biotec, Gladbach, Germany) followed by
positive selection through paramagnetic columns (LS columns;
Miltenyi Biotec) according to the manufacturer's instructions. The
purity of the selected cell fraction was N95%.
2.4. Stimulation of DC by P-gp molulators
P-gpmodulator (VRP, CsA, and VLX) was dissolved in culture media
andwas added to cultures of isolatedDC in six-well plates (106 cells/ml;
2 ml/well). Media alonewas used as negative control. For the analysis of
apoptosis, DCwere stimulated with LPS or left without any stimuli, and
analyzed over time by staining of phosphatidylserine translocationwith
FITC-annexin V in combination with propidium iodine kit (BD
Pharmingen) according to the manufacturer's instructions.
2.5. Flow cytometric analysis
On day 6, BM-DC were harvested, washed with phosphate buffered
saline (PBS) and resuspended in ﬂuorescence activated cell sorter
(FACS) washing buffer (2% fetal bovine serum and 0.1% sodium azide in
PBS). The cells were ﬁrst blocked with 10% (v/v) normal goat serum for
15 min at 4 °C and stained with phycoerythrin (PE)-conjugated anti-
H-2Kb [major histocompatibility complex (MHC) class I], anti-I-Ab11c+ DC.
LPS siRNA+LPS
382±23## 240±12**
630±47## 342±42**
ed (##Pb0.01 vs unstimulated DC (medium) **Pb0.01 vs LPS-stimulated DC).
e LPS (200 ng/ml) stimulation for 24 h. Analysis of IL-1α and IL-12p70 production was
n.
Fig. 1. Expression ofmdr-1 andmdr-3 during DC development. (A)mdr-1 andmdr-3 gene expression levels during DC development for 2, 4, and 6 days. The data are representative of
three experiments that gave similar results. (B) Quantitation ofmdrmRNA levels by real-time RT-PCR. Samples were taken for RNA preparation, and quantitative real-time RT-PCR
analyses were performed. A signiﬁcant difference in expression between each group was detected. The histogram is from one out of three representative experiments. (C) For P-gp
protein analysis, cell lysates were prepared and blotted with anti-P-gp and anti-β-actin Abs. (D) Confocal microscopy analysis of P-gp expression during DC development. The DC
were stained for CD11c+ (green), P-gp (red), and DAPI (blue). The data represent the means (±SD) of four separate experiments. (**Pb0.01 vs control groups).
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nate (FITC)-conjugated anti-CD11c (Pharmingen, San Diego, CA) for
30 min at 4 °C. The stained cells were analyzed using a FACSCalibur ﬂow
cytometer (BD Biosciences) (Table 1).2.6. Cytokines assay
DC were ﬁrst blocked with 10% (v/v) normal goat serum for 15 min
at 4 °C and then stained with FITC-conjugated CD11c+ antibody for
30 min at 4 °C. The cells stained with the appropriate isotype-matched
Ig were used as negative controls. The cells were ﬁxed and permeabi-
lized with the Cytoﬁx/Cytoperm kit (BD Pharmingen) according to
manufacturer's instructions. Intracellular IL-12p40/p70 and IL-10 were
stained with ﬂuorescein R-phycoerythrin (PE)-conjugated antibodies
(Pharmingen) in a permeation buffer. The cells were analyzed using
FACSCalibur ﬂow cytometer with the CellQuest program. Furthermore,
murine IL-12p70, IL-4, IL-6, IL-1α, and IFN-γ from DC were measured
using an ELISA kit (BD Pharmingen), according to manufacturer's
instructions.2.7. Mixed lymphocyte reaction
Responder T cells, which participate in allogeneic T-cell reactions,
were isolated passing throughmononuclear cells from spleen of BALB/
c mice in a MACS column (Miltenyi Biotec). Staining with ﬂuorescein
isothiocyanate (FITC)-conjugated anti-CD4 and anti-CD8 antibodies
(BD Pharmingen) revealed that they consisted mainly of CD4+ and
CD8+ cells (N95%). The lymphocyte population was then washed
twice in PBS and labeled with CFSE, as previously described [23]. The
cells were resuspended in 5 μM CFSE in phosphate-buffered saline
(PBS). After being shaken for 8 min at room temperature, the cells were
washed once in pure fetal bovine serum(FBS) and twice in PBSwith 10%
FBS. DC (1×104) or DC exposed to VLX (25 and 50 μM/ml) or LPS
(200 ng/ml) for 24 h were cocultured with 1×105 allogeneic CFSE--
labeled T lymphocytes in 96-well, U-bottom plates (Nunc). A negative
control (CD4+ and CD8+ lymphocytes alone) and a positive control
(CD4+andCD8+ lymphocytes in 5 μg of Concanavalin A)were included
for each experiment. After 4 days, the cells were harvested and washed
in PBS. CFSE dilution optically gated lymphocyteswere assessed by ﬂow
cytometry.
Fig. 2. DCmaturation increased expression ofmdr-1 and P-gp, but notmdr-3. DCwere generated as described inMaterials andmethods. On day 6, the cells were cultured under standard
conditions for another 6 h and for time course experiments in the presence of 100 or 200 ng/ml LPS. Cells were then harvested and analyzed by quantitative real-time RT-PCR (A) and
Western blot (B). To assess P-gp activity, DCwere loadedwith the ﬂuorescent probe Rhodamine 123 for 30 min at 37 °C, washed, and incubated for a another 30 min at 37 °C to determine
dye extrusion. The ﬂuorescence was measured by ﬂow cytometry (C). The data represent the means (±SD) of three separate experiments. (**Pb0.01 vs untreated DC groups).
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mdr-1 and mdr-3 PCR primers used were as follows: forward 5′-
ACATTCTTGGCTGACTTGCG-3′ and 5′-TATAGTTTTGGCTGGGCGTGG-3,
reverse 5′-AAAACACCGTCCTGAAGGCT-3′ and 5′-ATTTCTCCAGCAC-
CAGGGAC-3′, respectively. Quantitative amounts of each gene were
standardized against the GAPDH housekeeping gene. Real-time PCR
was performed using a BioRad MiniOpticon System (BioRad Labora-
tories Ltd, Missouri, USA.) with SYBR green ﬂuorophore. Reactions
were performed in a total volume of 20 μl-including 10 μl 2× SYBR
Green PCRmasterMix (Applied Biosystems, Carlsbad, CA, USA), 1 μl of
each primer at 10 μM concentration and 1 μM of the previously
reverse-transcribed cDNA template. The protocols used were as
follow: denaturation (95 °C for 10 min), ampliﬁcation was repeated
40 times (95 °C for 30 s, 55 °C for 30 s, 72 °C for 30 s and acquisition
temperature for 15 s). For each sample, ddCt (crossing point) values
were calculated as the Ct of the target gene minus Dt of the GAPDH
gene. Gene expression was derived according to the equation 2−ddCT,
and changes in gene expression were expressed as relative to basal.
2.9. siRNA studies
DC were transfected with 100 nM siRNA speciﬁc to P-gp (Santa
Cruz, CA, USA) and a negative control siRNA according to the
manufacturer's protocol (Santa Cruz). After 24 h incubation, the DC
were rinsed with PBS and used for further analysis as described above
(Table 2).2.10. Cytoplasmic extracts and Western blot
The cells (DC) were exposed to VRP, CsA, and VLX for 24 h of
incubation at 37 °C, cells were washed twice with cold PBS and lased
with modiﬁed RIPA buffer (1.0% NP-40, 1.0% sodium deoxycholate,
150 nMNaCl, 10 mMTris–HCl [pH 7.5], 5.0 mM sodiumpyrophosphate,
1.0 mM NaVO4, 5.0 mM NaF, 10 mM/ml leupeptin, and 0.1 mM
phenylmethylsulfonyl ﬂuoride) for 15 min at 4 °C. Lysates were cleared
by centrifuging at 14,000 g for 20 min at 4 °C. The protein content of cell
lysates was determined using theMicro BCA assay kit (Pierce, Rockford,
IL). Equivalent amounts of proteins were separated by 10% SDS-PAGE
and analyzed by Western blotting using a P-glycoprotein (Abcam,
Cambridge, MA, USA) and anti-β-actin (Santa Cruz) mAb for 3 h, as
described by themanufacturer of the antibodies. Following thewash for
three times with TBST, membranes were incubated with secondary
HRP-conjugated anti-mouse IgG for 1 h. After washing, the blots were
developed using the ECL system (GE healthcare life sciences, NJ, USA),
by following manufacturer's instructions.2.11. Statistics
All results were expressed as the means±SD of the indicated
number of experiments. Statistical signiﬁcance was estimated using a
Student's t-test for unpaired observations, and the differences were
compared with regard to statistical signiﬁcance by one-way ANOVA,
followed by Bonferroni's post hoc test. The categorical data from the
Fig. 3. VLX, but not VRP or CsA, suppresses P-gp levels during dendritic cells maturation. DC were treated VRP, CsA, or VLX at the noted concentrations, in the absence
or presence of LPS (200 ng/ml). (A) Total RNA was extracted and quantitative PCR was done using sequence-speciﬁc primers to mdr-1 gene and GAPDH. GAPDH was
included as an internal control. Western blot analysis showed the protein expression of P-gp in DC treated with VRP, CsA, and VLX. The cells were treated with VRP,
CsA, or VLX at the indicated doses for 24 h (B), or with 200 ng/ml LPS (C), and then collected for western blot analysis (20 μg/lane). The data are representative of
three experiments that gave similar results.
1352 J.S. Lee et al. / International Immunopharmacology 11 (2011) 1348–1357fertility test were subjected to statistical analysis via Chi-square test. A
P of b0.01 was considered signiﬁcant.
3. Results
3.1. Up-regulation of mdr-1, mdr-3 and P-gp during DC development
Monocytes, T cells, NK-cells, and skin dendritic cells are known to
express themdr-1 andmdr-3 gene product, P-gp [18, 24]. In the initial
series of experiments, we attempted to determine whether mdr gene
expression inﬂuences DC development. Bone marrow-derived DC
were cultured for 2, 4, and 6 days in OptiMEM supplemented with
20 ng/ml of GM-CSF and 20 ng/ml of IL-4. The expression levels of
mdr-1 and mdr-3 were assessed using RT-PCR and quantitative real-
time PCR, normalizing the amounts of mRNA for targeted genes to the
mRNA levels of the GAPDH gene. Our quantitative real-time PCR
results clearly indicate that expression ofmdr-1 andmdr-3was highly
up-regulated during DC development (Fig. 1A and B). P-gp protein
expression was evaluated during the monocyte to immature DC
development by confocal microscopy and Western blot analysis. By
western blot analysis, we found a pronounced up-regulation of the
170 kDa P-gp protein during differentiation from monocytes to
immature DC (Fig. 1C). Cultured DC were co-stained for P-gp andthe DC marker, CD11c+. DC expressing P-gp (red) was also positive
for DC marker CD11c+ (green), suggesting that these cells are in fact
increasing P-gp expression during DC development (Fig. 1D).3.2. Increased mdr-1 gene expression during DC maturation, but not
mdr-3
We found that mdr-1 and mdr-3 genes were essential for DC
development, and next examined the individual role of these genes in
DC maturation. To determine if expression of mdr-1 and mdr-3 genes
is modulated during DC maturation we examined the expression of
these genes in LPS-induced DC maturation. As shown in Fig. 2, the
expression ofmdr-1, but notmdr-3, is up-regulated by DC maturation
in a dose- and time-dependent manner. These data indicate that
mdr-1 gene expression is required for DC development as well as DC
maturation. This was further conﬁrmed on the protein level by
western blot analysis (Fig. 2B), as the level of P-gp expression in-
creased during DC maturation. Next, the efﬂux activity of the
transmembrane P-gpwas studied using rhodamine dye as a substrate.
As shown in Fig. 2C, DC maturation also corresponded with an
increase P-gp efﬂux activity, indicating that P-gp activity was in-
creased during DC maturation.
AB
C
Fig. 4. VLX treatment suppresses the expression of co-stimulatory molecules and impairs cytokine production in LPS-induced DCmaturation. DC were harvested and analyzed using
two-color ﬂow cytometry. The cells were gated on CD11c+. VLX was added to the DC for 24 h at concentrations of 25 and 50 μM, and stimulation was induced with 200 ng/ml LPS.
Surface molecule expression was then analyzed (A). The histogram shown is from one out of four representative experiments. The numbers indicate mean ﬂuorescence indensity
(MFI) (B) DC were stimulated with VRP (20 μM, such as P-gp blocker), or VLX (50 μM, such as P-gp suppressor) for 24 h, with or without LPS. This ﬁgure represents the analysis of IL-
12p40p70 and IL-10 expression in CD11c+DC by intracellular cytokine staining after 24 h of LPS stimulation. The numbers indicate the percentages of CD11c+ cells expressing IL-
12p40p70 or IL-10. (C) Analysis of IL-1α, IL-6, IL-10, and IL-12p70 production was measured by ELISA with magnetic bead-puriﬁed DC (1×106 cells) 24 h after LPS stimulation
(200 ng/ml). The data represent the means (±SD) of four separate experiments. (**Pb0.01 vs control groups).
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Fig. 5. P-gp depleted-DC impairs proliferation of allogeneic T cells, and inhibits Th1/2 polarization. The DC were incubated for 24 h in medium alone, positive control (Concanavalin
A), in either 25 or 50 μM VLX, 200 ng/ml LPS, or in VLX coupled with LPS. The treated DC were harvested and thoroughly washed to remove the VLX and LPS. A mixed lymphocyte
reaction was allowed to proceed for 3 days, as described in the Materials and methods section of this article. (A) T cell proliferation was analyzed by ﬂow cytometry and is presented
as a percentage of dividing cells. (B) Supernatants were examined for cytokine release after 72 h. IL-2, IL-4, and IFN-γ in culture supernatants were measured by ELISA. Data are
expressed as pg/ml/106 cells±SD of triplicate cultures. Medium represents the chemically untreated control group. (**Pb0.01 vs control groups).
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expression
To verify the function of P-gp in DC, aWestern blot analysis was used
to detect changes in P-gp expression following treatment with speciﬁc
inhibitors, includingVRP,CsA, andVLX.Generally, these speciﬁc inhibitors
of P-gp have been reported to block drug efﬂux and function of ATP-
binding cassette protein subfamily B (ABCB) transport, but not down-
regulate the protein expression [25–27]. In preliminary experiments, DC
were treated with VRP, CsA, and VLX, and we observed no marked
differences in the percentage of dead cells, as evidenced by CD11c+ cell
and annexin-V/propidium iodide (PI) staining (data not shown). As
shown in Fig. 3A and B, we found that VRP and CsA did not affect
expression of P-gp or mdr-1 expression, but VLX treatment signiﬁcantly
decreased the expression level of P-gp. Moreover, VLX treatment
suppressed P-gp expression in LPS-induced DC maturation (Fig. 3C).
3.4. P-gp suppressor inhibits DC maturation and activation through IL-12
production
The observed changes in expression of P-gp during DC maturation
suggest that VLX exposure may lead to a profound regulation of the
phenotypic and functional maturation of DC.We then investigated the
effects of VLX on DC maturation. As shown in Fig. 4A, VLX treatment
signiﬁcantly attenuated surface expression of CD80, CD86, MHCclasses I and II on the CD11c+ cells in a dose-dependent manner in
comparison to the control group. Exposure to VLX in the presence of
LPS resulted in impaired expression of MHC classes I and II.
Interestingly, a signiﬁcant down-regulation of the costimulatory
molecules, CD80 and CD86, was also observed under these conditions.
It is known that inducing DC activation will result in the release of
cytokines, including IL-1α, IL-6, IL-10, and IL-12, and this can be
modulate DC-mediated T cell immune responses [28, 29]. IL-12
production was identiﬁed previously as a speciﬁc marker of DC
activity, a critical marker for DC maturation, and can be used as a
select Th1-dominant adjuvant [30]. We next assess the ability of DC to
generate pro-inﬂammatory cytokines. To do this, we analyzed the
production of cytokines following treatment with each P-gp blocker
(such as VRP) and suppressor (such as VLX) from both immature and
mature DC. As shown in Fig. 4B and C, DC stimulated with VLX
expressed small amounts of IL-1α, IL-10, and IL-12, in comparison to
unstimulated DC. Interestingly, the P-gp blocker VRP had no effect on
cytokine levels during DC maturation. These data indirectly indicate
that P-gp is necessary for DC maturation and activation.
3.5. P-gp of DC is required for DC-mediated T cells polarization and
proliferation
Changes on surface molecule expression and cytokine production
from P-gp modulated-DC show that the down-regulation of P-gp
Fig. 6. The down-regulation of P-gp inhibits DC development and differentiation. As a measure of development and differentiation, we quantiﬁed the percentage of cells staining for
each marker protein that was associated with the DC arbor. The DC marker proteins CD11c+ (A) and CD86 were already preferentially localized to the dendritic arbor on day 2, and
their polarization increased to immature levels by day 6 (B). The percentage of cells expressing these proteins associated with the dendritic membrane increased signiﬁcantly during
DC development. DC were cultured with GM-CSF, IL-4, with or without VLX then collected and immunophenotyped on the days indicated. Cells were labeled with the designed
monoclonal antibodies and analyzed by ﬂow cytometry. The quadrants shown were set based on isotype control staining. The data are representative of three experiments that gave
similar results.
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changes associated with the maturation of DC. However, these results
did not permit us to exclude the possibility that P-gp induces a general
inhibition of the physiological functions of DC. Therefore, we sought to
determine if VLX-induced decrease of P-gp on DC is associated with
the reduced proliferation, differentiation, and cytokine production in
T cells. More speciﬁcally, we attempted to determine whether the
stimulation of DC with a P-gp suppressor alters the ability of the DC
cells to activate T cells in a mixed lymphocyte reaction (MLR). As
shown in Fig. 5A and B, the LPS-treated DC exhibited a far more
profound proliferation than did the controls, whereas treatment with
a P-gp suppressor appeared to impair to proliferation responses in the
allogeneic T cells elicited by the LPS-stimulated DC. Signiﬁcant
inhibition of T cell proliferation occurred at concentrations of VLX as
low as 25 μM in MLR stimulated assays. The concentrations of IL-2,
IL-4, and IFN-γ measured in 72-h co-culture supernatants, when cell
counts are approximately equal, were also reduced, suggesting a
possible cytokine-dependent mechanism and inhibit DC maturation
following treatment with P-gp suppressor (VLX).
3.6. P-gp suppressor blocks DC development
While the effects of P-gp suppressor treatment during DC
development have not been previously investigated, our data suggest
that P-gp is a very important to DC differentiation, maturation, and T
cell immunity. To investigate possible roles of P-gp in DC develop-
ment, a P-gp suppressor, at nontoxic does, was added to interstitial DC
cultures. The addition of the P-gp suppressor VLX markedly inhibited
DC development as seen by CD11c-FITC values (Fig. 6). In addition,when analyzing marker surface expression, VLX treatment had
suppressive effect on CD86 expression. The DC marker proteins such
as CD11c and CD86 were already preferentially localized to the DC
membrane during DC development. Moreover, the percentage of cells
expressing these proteins associated with the dendritic membrane
increased signiﬁcantly during DC activation.
4. Discussion
This is, to the best of our knowledge, the ﬁrst report of the effects of
P-glycoprotein (P-gp) expression levels on the phenotype, and the
differentiation and development capabilities of murine bone marrow-
derived DC. The aim of the work described here was to investigate
whether regulation of P-pg, a protein previously shown to be involved
in the migration of mature DC, altered the development of DC and DC-
mediated T cell immunity [16], the functional and development
capabilities have not been assessed. Thephysiological roleof P-gp is not
completely understood; however, it has been related to multi-drug
resistance in cancer cells [31], T cells immunity [32], and DC migration
[16]. Previous reports show that P-gp is a trans-membrane protein, a
molecule of the ABC transporter superfamily, and is well-known that it
mediates efﬂux of chemotherapeutic agents from the intracellular
environment, thereby contributing to drug resistance [33, 34].
In this study, we suggest that P-gp expression alters physiological
functions of DC. Down-regulation of P-gp inhibits the maturation and
activation of DC, as demonstrated by low expression of costimulatory
molecules on DC surfaces and the reduced cytokine levels, including
IL-1α, IL-10, and IL-12 (Fig. 4). Moreover, the production of IFN-γ, IL-4,
and IL-2 cytokineswas signiﬁcantly decreased in P-gp suppressed-DC in
1356 J.S. Lee et al. / International Immunopharmacology 11 (2011) 1348–1357a co-culture system with T cells (Fig. 5). Functionally, the down-
regulation of P-gp in DC inhibited primary T cell stimulatory activity in
an allogeneic MLR, and drives Th1/Th2 polarization in both CD4+ and
CD8+ T cells.
DC are the most potent APC that amplify and initiate immune
responses. In addition, DC play a crucial role in peripheral tolerance
mechanisms, induce different types of immunity and tolerance,
recognizing tumors, while capable of preventing immune responses
against environmental antigens andself tissues [3, 33, 35–38].Moreover,
DC are among the benign cells affected by anti-cancer drugs, inducing an
immune deﬁcient state [39]. Therefore,we investigated the function role
of P-pg and the inﬂuence of anti-cancer drugs on DC function.
Here, we show that the down-regulation of P-gp inhibits expression
of CD80, CD86, MHC I, and MHC II on DC. Moreover, P-gp suppressor
(VLX)-treated DC expressed reduced levels of IL-1α, IL-10, and IL-12
following LPS-induced maturation (Fig. 4). These results suggest that
P-gp directly inhibits maturation and activation of DC. In addition, we
report that DC differentiation requires mdr-1, but not mdr-3. Down-
regulation of P-gp following VLX treatment during DC differentiation
resulted in alteration of cell morphology and phenotype (Figs. 1 and 2).
When DC were cultured in the presence of a P-gp suppressor during
development, cells displayed decreased levels of CD11c+. In addition to
phenotypic andmorphological changes, the down-regulation of P-gp in
DC induced to differentiate with LPS treatment resulted in altered DC
function. Speciﬁcally, these DC exhibited lowered secretion of IL-1α and
IL-12p40p70, and a reduced capacity to stimulate allogeneic T cell
proliferation. This reduction in IL-12 production suggests that these cells
might beweaker in inducing a Th1 response. Taken together, this report
shows thatmurineDCexpresses theABC-transporter P-gpon theplasma
membrane (Fig. 1C and D), and was capable of actively extruding
chemotherapeutic drugs from the cells. We further propose that P-gp
activity is required for DC development and differentiation, and when
combined with prior reports on its requirement in DC migration, this
transporter becomes even more interesting as a potential target in DC-
based immunotherapies. For example, increasing P-gp expression in DC
could perhaps result in more potent APC, allowing for use as a tool
combined with chemo-immunotherapy treatments.
In conclusion, down-regulation of P-gp by VLX inhibits the
differentiation of DC and cytokine production, such as IL-1, IL-10,
and IL-12 during DC maturation. Moreover, the P-gp-decreased DC
inhibits T cell proliferation and cytokine production. In addition, these
observations are important to consider when developing new P-gp
modulators and the development of therapeutic adjuvants for the
treatment of DC-related acute and chronic diseases.
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